ACRV Acrivon Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ACRV
Price (delayed)
$2.03
Market cap
$63.85M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.24
Enterprise value
$25.02M
Relative Growth:
Rel. Growth:
9
Relative Strength:
Rel. Strength:
51
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
5
We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our
Highlights
Acrivon Therapeutics's debt has decreased by 23% YoY and by 7% QoQ
The EPS has grown by 19% YoY
ACRV's quick ratio is down by 36% YoY and by 7% from the previous quarter
ACRV's equity is down by 34% YoY and by 11% QoQ
Key stats
What are the main financial stats of ACRV
Market
Valuations
Earnings
Shares outstanding
31.46M
Market cap
$63.85M
Enterprise value
$25.02M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.44
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$94.41M
Net income
-$85.96M
EBIT
-$85.96M
EBITDA
-$83.78M
Free cash flow
-$73.2M
Per share
Balance sheet
Liquidity
EPS
-$2.24
EPS diluted
-$2.24
Free cash flow per share
-$1.9
Book value per share
$4.56
Revenue per share
$0
TBVPS
$4.12
Total assets
$158.58M
Total liabilities
$15.55M
Debt
$3.26M
Equity
$143.04M
Working capital
$124.98M
Debt to equity
0.02
Current ratio
10.31
Quick ratio
10.25
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-46.1%
Return on equity
-50.8%
Return on invested capital
-64.1%
Return on capital employed
-59.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACRV stock price
How has the Acrivon Therapeutics stock price performed over time
Intraday
-5.58%
1 week
7.41%
1 month
6.28%
1 year
-74.07%
YTD
-66.28%
QTD
12.15%
Financial performance
How have Acrivon Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$94.41M
Net income
-$85.96M
Gross margin
N/A
Net margin
N/A
ACRV's net income is down by 25% year-on-year and by 2.6% since the previous quarter
The operating income has declined by 24% year-on-year
Price vs fundamentals
How does ACRV's price correlate with its fundamentals
Growth
What is Acrivon Therapeutics's growth rate over time
Valuation
What is Acrivon Therapeutics stock price valuation
P/E
N/A
P/B
0.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 19% YoY
The P/B is 37% below the last 4 quarters average of 0.7
ACRV's equity is down by 34% YoY and by 11% QoQ
Efficiency
How efficient is Acrivon Therapeutics business performance
The ROIC has contracted by 16% from the previous quarter and by 11% YoY
Acrivon Therapeutics's return on equity has decreased by 14% QoQ and by 7% YoY
The ROA has contracted by 13% from the previous quarter and by 7% YoY
Dividends
What is ACRV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACRV.
Financial health
How did Acrivon Therapeutics financials performed over time
ACRV's current ratio is down by 36% YoY and by 8% from the previous quarter
ACRV's quick ratio is down by 36% YoY and by 7% from the previous quarter
Acrivon Therapeutics's debt is 98% lower than its equity
ACRV's equity is down by 34% YoY and by 11% QoQ
Acrivon Therapeutics's debt has decreased by 23% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.